Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

We explore the immense potential of gamma delta T cells, and the challenges in sourcing and scaling up sufficient volumes to ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed an investigational therapy for ...

Also known as a polymyxin B haemoperfusion (PMX), Toraymyxin is a haemoperfusion device that removes endotoxin, a toxic ...

RAPT Therapeutics’ CEO Brian Wong said there was no “viable path forward” for the compound. Image credit: Shutterstock/Andrii Yalanskyi. RAPT Therapeutics has called it quits on a clinical programme ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

The former health minister predicted a bright future for UK trials and outlined steps to ensure clinical research thrives.

Research Grid has raised a $6.5m seed funding round led by Fuel Ventures, to improve the success rate of clinical trials.

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with solid ...

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.